Page 80 - 80 guidelines for the treatment of malaria_opt
P. 80

nd
              Guidelines for the treatment of malaria – 2  edition


            1.     DESIgN LIMITATIONS: is the design of the trials flawed for a set outcome?
            For hard outcomes, such as death, the panel considered the adequacy of the allocation
            concealment.
            For softer outcomes, such as vomiting, the panel also considered blinding.
            Sensitivity analyses, excluding poor quality trials, enabled the panel to make judgements
            about whether variations in methodological quality between trials constituted a limitation
            or not, and, if so, if this was serious or very serious.

            2.    INCONSISTENCy: is the effect size similar across trials for a set outcome?
            The panel considered the 95% confidence intervals for each trial reporting an outcome
            and whether they overlapped or not.
                                     2
            The panel also considered the I  value and viewed the forest plot to make a judgement.
            3.    INDIrECTNESS: is there sufficient evidence for your population and drugs
                  of interest for a set outcome?
            The panel considered the trial populations, the population of interest and whether they
            would expect differences in the performance of either the intervention or the control in
            different settings.
            If the panel only had partial information on the performance outcome in the population
            of interest, then drugs were downgraded by 1 (serious indirectness).
            If the panel only had limited information on the performance outcome in the population
            of interest, then drugs were downgraded by 2 (very serious indirectness).

            4.    IMPrECISION: are there sufficient data and or clear relative effects for a set
                  outcome?
            The panel agreed that the borders of appreciable benefit and harm were a relative risk
            value of 0.75 < RR > 1.25.
            If the 95% CI for the pooled estimate included appreciable benefit (or appreciable harm)
            and no significant difference between the intervention and control group, then the panel
            downgraded by 1 (serious imprecision).
            If the 95% CI for the pooled estimate included appreciable benefit and appreciable harm
            with the intervention, then the panel downgraded by 2 (very serious imprecision).


            The GRADE quality rating for RCT evidence may, therefore, be “downgraded” by one,
            two or three levels from high to moderate to low or very low quality, and it is rated on
            the following four-point scale:

    66
   75   76   77   78   79   80   81   82   83   84   85